Table 3 Results of the base case model after 3 years
% progress to ESRD (95%CI) | Life years lived (95%CI) | Costs (€) (95%CI) | |
|---|---|---|---|
Moxonidine | 7.5% (3.5–12.7) | 2.950 (2.937–2.959) | €9,858 (5,501–16,174) |
Nitrendipine | 38.9% (31.8–45.8) | 2.907 (2.882–2.927) | €37,472 (27,957–49,478) |